Stella Pharma Corporation
Confirmed Research Framework for New Treatment Concept ‘B-NIT’｜July 2026
Our company has collaborated with Okayama University to establish the research framework for a Phase I clinical trial of the B-NIT therapy and has signed an outsourced development contract. We are preparing for physician-led clinical trials, and it is expected to have minimal impact on our performance in fiscal year 2027.
Key Figures
- Research Period: April 1, 2026 to March 31, 2027
- Contract Partner: Outsourced research and development agreement with Okayama University
- Target Disease: Unresectable BRAF-negative advanced melanoma
AI要約
Overview of Research and Development
Our company has jointly with Okayama University established the research framework for creating a protocol for a Phase I clinical trial using B-NIT (Boron Neutron Immunotherapy) and has signed an outsourced research and development agreement. B-NIT is a new treatment concept combining BNCT and immunotherapy, targeting patients with advanced melanoma. The study is scheduled from April 2026 to March 2027, aiming to initiate physician-led clinical trials in the future.
Future Outlook and Impact
Progress of this research is expected to have a minimal impact on our performance for the fiscal year ending March 2027. We will promptly disclose any new developments or important matters and will proceed with efforts towards clinical trial initiation and practical application of the therapy as progress is made.
Stella Farm Co., Ltd.
Company overview · Stock price · Financial data · All IR
